# Molecular and clinical characterization of atypical central neurocytomas: implications for diagnosis and treatment strategies

**Authors:** Feixia Sun, Zuocheng Yang, Ronghua Kong, Song Han

PMC · DOI: 10.1007/s12672-024-01172-0 · Discover Oncology · 2024-07-27

## TL;DR

This study explores the molecular and clinical features of atypical central neurocytomas to improve diagnosis and treatment strategies.

## Contribution

The study identifies genetic alterations and treatment outcomes in atypical central neurocytomas, offering new insights into their management.

## Key findings

- Complete resection significantly improves survival rates in atypical central neurocytoma patients.
- Genetic alterations in pathways like cAMP, MAPK, and Ras are linked to aggressive tumor behavior.
- Postoperative radiotherapy does not improve outcomes after complete tumor resection.

## Abstract

This study aimed to investigate the histological and molecular characteristics of atypical central neurocytomas (CNs) and evaluate their clinical treatment outcomes, with the aim of identifying reliable biomarkers for differentiation and optimal treatment strategies.

We conducted a retrospective study including 61 patients diagnosed with CNs. Clinical data, neuroimaging, and pathological findings were analyzed. RNA sequencing was performed on tumor tissues to identify differentially expressed genes.

Histological atypia and the Ki-67 index showed no significant impact on progression-free survival (PFS) or overall survival (OS). RNA sequencing identified significant genetic alterations in pathways such as neuroactive ligand–receptor interaction, cAMP, MAPK, and Ras signaling. Differently expressed genes included AMOTL1, PIK3R3, TGFBR1, SMO, COL4A6, MGP, SOX4, IGF2, SLIT1, and CKS2. The five-year OS rate (p = 0.015) and PFS rate (p = 2.00 × 10−6) were significantly higher in the complete resection (CR) group compared to the incomplete resection (IR) group. Postoperative radiotherapy did not affect OS or PFS in the CR group. The five-year PFS rate (p = 3.80 × 10−5) was significantly longer in patients in the CR group who did not receive radiotherapy compared to those in the IR group who did receive radiotherapy. The extent of surgical resection and operative approaches were found to be irrelevant to perioperative complications and dysfunctions at the last follow-up.

CR is crucial for a better prognosis in patients with atypical CNs. Additional radiotherapy after CR offers little benefit. Histological atypia and the Ki-67 index are not effective in distinguishing between atypical and typical CNs. Identified genetic alterations provide insights into the aggressive behavior of atypical CNs, suggesting potential therapeutic targets and underscoring the need for further research to optimize treatment strategies.

## Linked entities

- **Genes:** AMOTL1 (angiomotin like 1) [NCBI Gene 154810], PIK3R3 (phosphoinositide-3-kinase regulatory subunit 3) [NCBI Gene 8503], TGFBR1 (transforming growth factor beta receptor 1) [NCBI Gene 7046], SMO (smoothened, frizzled class receptor) [NCBI Gene 6608], COL4A6 (collagen type IV alpha 6 chain) [NCBI Gene 1288], MGP (matrix Gla protein) [NCBI Gene 4256], SOX4 (SRY-box transcription factor 4) [NCBI Gene 6659], IGF2 (insulin like growth factor 2) [NCBI Gene 3481], SLIT1 (slit guidance ligand 1) [NCBI Gene 6585], CKS2 (CDC28 protein kinase regulatory subunit 2) [NCBI Gene 1164]

## Full-text entities

- **Genes:** SOX4 (SRY-box transcription factor 4) [NCBI Gene 6659] {aka CSS10, EVI16, IDDSDF}, TGFBR1 (transforming growth factor beta receptor 1) [NCBI Gene 7046] {aka AAT5, ACVRLK4, ALK-5, ALK5, ESS1, LDS1}, SMO (smoothened, frizzled class receptor) [NCBI Gene 6608] {aka CRJS, FZD11, Gx, PHLS, SMOH}, AMOTL1 (angiomotin like 1) [NCBI Gene 154810] {aka CFCHS, JEAP}, MGP (matrix Gla protein) [NCBI Gene 4256] {aka GIG36, MGLAP, NTI}, SLIT1 (slit guidance ligand 1) [NCBI Gene 6585] {aka MEGF4, SLIL1, SLIT-1, SLIT3}, PIK3R3 (phosphoinositide-3-kinase regulatory subunit 3) [NCBI Gene 8503] {aka p55, p55-GAMMA, p55PIK}, IGF2 (insulin like growth factor 2) [NCBI Gene 3481] {aka C11orf43, GRDF, IGF-II, PP9974, SRS3}, CKS2 (CDC28 protein kinase regulatory subunit 2) [NCBI Gene 1164] {aka CKSHS2}, COL4A6 (collagen type IV alpha 6 chain) [NCBI Gene 1288] {aka CXDELq22.3, DELXq22.3, DFNX6}
- **Diseases:** tumor (MESH:D009369), CNs (MESH:D018306)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11283444/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11283444/full.md

---
Source: https://tomesphere.com/paper/PMC11283444